Page last updated: 2024-10-14

bay 63-2521

Description

riociguat: guanylate cyclase stimulator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

riociguat : A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11304743
CHEMBL ID2107834
CHEBI ID76018
SCHEMBL ID245457
MeSH IDM0533465

Synonyms (84)

Synonym
HY-14779
RIOCIGUAT,CAS:625115-55-1
bay 63-2521; bay 632521
bay-632521
riociguat
bay-63-2521
riociguat (jan/usan/inn)
D09572
adempas (tn)
unii-ru3fe2y4xi
methyl n-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1h-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-n-methylcarbamate
carbamic acid, n-(4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl)-n-methyl-, methyl ester
carbamic acid, (4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl)methyl-, methyl ester
riociguat [usan:inn:jan]
ru3fe2y4xi ,
methyl 4,6-diamino-2-(1-(2-fluorobenzyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl(methyl)carbamate
adempas
bay 63-2521
BCP9000382
625115-55-1
chebi:76018 ,
CHEMBL2107834
BCP0726000023
bay 63-2521,riociguat
PB25734
CS-0584
AKOS015900718
bay 632521
S8135
riociguatum
methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate
gtpl5257
methyl n-(4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl}pyrimidin-5-yl)-n-methylcarbamate
riociguat [usp-rs]
riociguat [usp monograph]
riociguat [usan]
riociguat [orange book]
riociguat [vandf]
riociguat [ep monograph]
riociguat [jan]
riociguat [inn]
riociguat [mi]
riociguat [who-dd]
SCHEMBL245457
methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate
WXXSNCNJFUAIDG-UHFFFAOYSA-N
c20h19fn8o2
[4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]methylcarbamic acid methyl ester
methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate
AC-27647
n-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-n-methylcarbamic acid methyl ester
riociguat (bay 63-2521)
DB08931
methyl n-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-n-methyl-carbaminate
mfcd19443708
NCGC00379065-03
AKOS032950011
riocguat-d3
1304478-72-5
BCP04750
FT-0760451
AS-19299
Q2154494
riociguate
AMY4218
DTXSID50978109
CCG-268912
NCGC00379065-05
EX-A2023
BCP23980
bay 63-2521-d3; bay 632521-d3; methyl [4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]methylcarbamate-d3
methyl n-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-n-methylcarbamate
NCGC00379065-04
gzo ,
methyl ~{n}-[4,6-bis(azanyl)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-~{n}-methyl-carbamate
riociguat-d3
riociguat (usp monograph)
c02kx05
methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)methylcarbamate
methyl n-(4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl)-n-methyl-carbaminate
methyl n-(4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)-n-methylcarbamate
riociguat (usp-rs)
riociguat (ep monograph)
EN300-7413126

Toxicity

ExcerptReference
" Areas covered: We aim to give an overview of the pathophysiology of PH, pharmacodynamics and pharmacokinetic properties, safety and efficacy of riociguat, including adverse events, contraindications and drug interactions."( Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder, C; Bonderman, D; Zotter-Tufaro, C, 2016
)
" Eligible RCTs were included that reported mortality, the change of EuroQol Group 5-Dmensional Self-report Questionnaire (EQ-5D) US index, N-terminal pro-B-type natriuretic peptide (NT-proBNP), or serious adverse events (SAEs)."( The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.
Huang, J; Xiong, B; Zheng, W; Zheng, X, 2018
)
" Other endpoints included plasma biomarkers and proportion of participants with treatment-emergent adverse events (AEs)."( A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Bush, E; Domsic, RT; Frech, T; Gordon, JK; Khanna, D; Lafyatis, R; Nagaraja, V; Spino, C; Steen, VD; Tsou, PS, 2019
)
" Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21."( Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Barberá, JA; Boonstra, A; Delcroix, M; Escribano Subias, P; Gall, H; Ghofrani, HA; Giannakoulas, G; Gomez Sanchez, MA; Grünig, E; Halank, M; Helmersen, DS; Hoeper, MM; Humbert, M; Jansa, P; Klose, H; Klotsche, J; Lange, TJ; Langleben, D; Meier, C; Mielniczuk, LM; Pepke-Zaba, J; Pittrow, D; Rosenkranz, S; Šimková, I; Simonneau, G; Snijder, RJ; Steringer-Mascherbauer, R; Tsangaris, I; Ulrich, S; Vachiéry, JL; Williams, E; Wirtz, H, 2021
)
" The common adverse events of riociguat were dyspepsia and peripheral edema, and no other serious adverse reactions were observed."( Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Gu, S; Li, M; Song, J; Ying, M; Zhao, R, 2021
)
"We confirmed that riociguat had better therapeutic effects in improving the hemodynamic parameters and exercise capacity in patients with CTEPH without inducing serious adverse events."( Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Gu, S; Li, M; Song, J; Ying, M; Zhao, R, 2021
)

Pharmacokinetics

ExcerptReference
" The aim of this double-blind, crossover, clinical pharmacological study in 30 healthy volunteers was to investigate potential pharmacodynamic and pharmacokinetic interactions between the 2 drugs."( Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.
Frey, R; Kirschbaum, N; Krätzschmar, J; Mück, W; Weimann, G; Wensing, G, 2011
)
" A single dose was given on Day 1, followed by a 48-h pharmacokinetic profile."( Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Becker, C; Blode, H; Cui, Y; Frey, R; Unger, S; Wang, Y; Wang, Z; Yoshikawa, K; Zhang, H; Zhao, X, 2016
)
"Thirty-six subjects (18 smokers; 18 non-smokers) were randomized and provided valid pharmacokinetic data."( Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Becker, C; Blode, H; Cui, Y; Frey, R; Unger, S; Wang, Y; Wang, Z; Yoshikawa, K; Zhang, H; Zhao, X, 2016
)
" The half-life of riociguat is approximately 12 h in patients and approximately 7 h in healthy individuals."( Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
Becker, C; Frey, R; Mück, W; Saleh, S; Unger, S; van der Mey, D, 2018
)
" For pharmacokinetic studies and the determination of riociguat in PH patients, a new, quick, easy, and sensitive UPLC-MS/MS approach was designed and validated."( Determination and pharmacokinetic study of riociguat by UPLC-MS/MS in human plasma.
Albayrak, M; Araz, O; Atila, A; Kadioglu, Y; Kocak, OF; Yaman, ME, 2022
)

Compound-Compound Interactions

ExcerptReference
"As an alternative to vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) are increasingly prescribed in combination with riociguat in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)."( In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Bertoletti, L; Delavenne, X; Hodin, S; Jacqueroux, E; Margelidon-Cozzolino, V; Mercier, C, 2020
)
" Subjects with inoperable CTEPH are randomized into either a BPA combined with riociguat or riociguat monotherapy group (2:1) and observed for 12 months after initiation of treatment."( Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial.
Gong, SG; He, J; Jiang, R; Li, HT; Li, Y; Liu, JM; Luo, CJ; Qiu, HL; Wang, L; Wu, WH; Yuan, P; Zhang, R; Zhao, QH, 2021
)
"This study aims to compare the efficacy and safety of BPA combined with riociguat and riociguat monotherapy for inoperable CTEPH."( Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial.
Gong, SG; He, J; Jiang, R; Li, HT; Li, Y; Liu, JM; Luo, CJ; Qiu, HL; Wang, L; Wu, WH; Yuan, P; Zhang, R; Zhao, QH, 2021
)

Bioavailability

ExcerptReference
" It is rapidly absorbed, displays almost complete bioavailability (94."( Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
Becker, C; Frey, R; Mück, W; Saleh, S; Unger, S; van der Mey, D, 2018
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)

Dosage Studied

ExcerptReference
" Riociguat must be administered three times daily and requires dosage adjustments."( Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop, BM, 2014
)
" However, their use can be complicated by potential drug interactions, adverse effects, dosing complexity, and cost."( Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Badesch, D; Benza, RL; D'Eletto, TA; Farber, HW; Gomberg-Maitland, M; Hassoun, PM; Hill, NS; Preston, I, 2015
)
" Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen."( Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Ackerstaff, J; Becker-Pelster, EM; Fey, P; Follmann, M; Geiss, V; Gerisch, M; Griebenow, N; Jautelat, R; Kern, A; Knorr, A; Kretschmer, A; Kroh, W; Lang, D; Li, V; Lustig, K; Mittendorf, J; Mondritzki, T; Redlich, G; Sandner, P; Schirok, H; Schlemmer, KH; Stasch, JP; Straub, A; Tinel, H; Trübel, H; Wunder, F, 2017
)
"5 mg three times daily) during an 8-week titration period, followed by an 8-week stable dosing period."( A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Bush, E; Domsic, RT; Frech, T; Gordon, JK; Khanna, D; Lafyatis, R; Nagaraja, V; Spino, C; Steen, VD; Tsou, PS, 2019
)
"In this retrospective multicentric study in patients initiating riociguat, dosing regimen, co-treatments and clinical characteristics were collected over a 2-year follow-up period."( Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France.
Bénard, N; Bensimon, L; Dallongeville, J; Hakme, A; Lamia, B; Lévy-Bachelot, L; Pouriel, M; Sitbon, O, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
soluble guanylate cyclase activatorAny compound that binds to and activates soluble guanylate cyclase (EC 4.6.1.2).
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyrazolopyridine
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GVesicular stomatitis virusPotency23.91850.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency16.93300.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency23.91850.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency23.91850.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)MEC0.03000.03000.21000.3000AID1448980
Guanylate cyclase soluble subunit alpha-1Rattus norvegicus (Norway rat)MEC0.03000.03000.21000.3000AID1448980
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (64)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1697156Inhibition of vascular remodeling activity in Sprague-Dawley rat model of hypoxia-induced pulmonary artery hypertension assessed as increase in body weight at 10 mg/kg, po administered daily for 2 weeks2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697126Antiproliferative activity against HLF1 cells assessed as reduction in TGFbeta-induced cell proliferation measured after 48 hrs by CCK8 assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697140Inhibition of CaMKKbeta phosphorylated recombinant human AMPK alpha1/beta1/gamma1 using 1-biotin as substrate incubated for 60 mins by HTRF assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1448981Clearance in rat hepatocytes at 1 uM up to 90 mins by LC-MS/MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1697161Inhibition of vascular remodeling activity in Sprague-Dawley rat model of hypoxia-induced pulmonary artery hypertension assessed as reduction in alpha-SMA expression in lungs at 10 mg/kg, po administered daily for 2 weeks by Western blot analysis2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697132Stimulation of sGC in HPASMC assessed as increase in intracellular cGMP level measured after 1 hr in absence of PDE5 inhibitor IBMX and presence of sGC inhibitor ODQ by cGMP-d2/europium cryptate reagent based HTRF assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697143Inhibition of AMPK in TGFbeta-induced HLF1 cells assessed as reduction in cell migration measured after 24 hrs by wound healing assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697157Inhibition of vascular remodeling activity in Sprague-Dawley rat model of hypoxia-induced pulmonary artery hypertension assessed as reduction in pulmonary artery medial thickness at 10 mg/kg, po administered daily for 2 weeks by H and E staining based dig2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697154Inhibition of vascular remodeling activity in Sprague-Dawley rat model of hypoxia-induced pulmonary artery hypertension assessed as weight ratio of right ventricle/left ventricle plus septum at 10 mg/kg, po administered daily for 2 weeks (Rvb = 0.63 No_un2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697133Stimulation of sGC in HPASMC assessed as increase in intracellular cGMP level measured after 1 hr in absence of PDE5 inhibitor IBMX and sGC inhibitor ODQ by cGMP-d2/europium cryptate reagent based HTRF assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1448989Terminal half life in iv dosed Wistar rat blood after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1448987Clearance in iv dosed Wistar rat blood after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1448991Oral bioavailability in Wistar rat administered via oral gavage after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1697144Inhibition of AMPK in hypoxia-induced HLF1 cells assessed as reduction in cell migration measured after 24 hrs by wound healing assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697141Inhibition of AMPK in TGFbeta-induced HPASMC assessed as reduction in cell migration measured after 24 hrs by wound healing assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1448986Volume of distribution at steady state in iv dosed Beagle dog after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1448990Terminal half life in iv dosed Beagle dog blood after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1697127Antiproliferative activity against HPASMC assessed as reduction in TGFbeta-induced cell proliferation measured after 48 hrs by CCK8 assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1551543Stimulatory activity at sGC in Sprague-Dawley rat thoracic aorta assessed as inhibition of norepinephrine-induced contraction by JZ100 strain guages based isometric analysis2019European journal of medicinal chemistry, Jul-01, Volume: 173Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
AID1697139Antiproliferative activity against HPASMC measured after 48 hrs under hypoxic condition by CCK8 assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697153Inhibition of vascular remodeling activity in Sprague-Dawley rat model of hypoxia-induced pulmonary artery hypertension assessed as right ventricular systolic pressure at 10 mg/kg, po administered daily for 2 weeks by catheter method (Rvb = 26.2 mmHg)2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1448979Plasma clearance in iv dosed Beagle dog after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1697142Inhibition of AMPK in hypoxia-induced HPASMC assessed as reduction in cell migration measured after 24 hrs by wound healing assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1551544Stimulatory activity at sGC in Sprague-Dawley rat thoracic aorta assessed as inhibition of norepinephrine-induced contraction at 1 uM by JZ100 strain guages based isometric analysis relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
AID1697138Antiproliferative activity against HLF1 cells measured after 48 hrs under hypoxic condition by CCK8 assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1551546Cardioprotective activity in Langendorff perfused Sprague-Dawley rat heart assessed as reduction of coronary perfusion pressure2019European journal of medicinal chemistry, Jul-01, Volume: 173Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
AID1697129Vasodilating activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions at 1 uM relative to control2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697131Stimulation of sGC in HPASMC assessed as increase in intracellular cGMP level at 100 uM measured after 1 hr in absence of PDE5 inhibitor IBMX by cGMP-d2/europium cryptate reagent based HTRF assay relative to control2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697155Inhibition of vascular remodeling activity in Sprague-Dawley rat model of hypoxia-induced pulmonary artery hypertension assessed as decrease in ratio of RV/tibial length at 10 mg/kg, po administered daily for 2 weeks2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1448985Volume of distribution at steady state in iv dosed Wistar rat after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1697135Stimulation of sGC in HPASMC assessed as increase in intracellular cGMP level at 100 uM measured after 1 hr in presence of PDE5 inhibitor IBMX by cGMP-d2/europium cryptate reagent based HTRF assay relative to control2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1697136Stimulation of sGC in HPASMC assessed as increase in intracellular cGMP level at 100 uM measured after 1 hr in presence of PDE5 inhibitor IBMX and sGC inhibitor ODQ by cGMP-d2/europium cryptate reagent based HTRF assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
AID1448980Stimulation of rat recombinant sGCalpha1 subunit expressed in CHO cells using alpha-[32P]GTP as substrate assessed as >=3 fold increase in [32P]cGMP formation after 10 mins by radioimmunoassay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1448992Oral bioavailability in Beagle dog administered via oral gavage after 24 hrs by LC-MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
AID1697128Vasodilating activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of Novel Pyrazolo[3,4-
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (247)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (1.21)29.6817
2010's168 (68.02)24.3611
2020's76 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (18.50%)5.53%
Reviews75 (29.53%)6.00%
Case Studies10 (3.94%)4.05%
Observational3 (1.18%)0.25%
Other119 (46.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]